MedTrace Logo

Technetium Tc 99m Demobesin-4 for Imaging Procedures in Patients With Prostate Cancer

NCT00989105 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2012-02-28

No results posted yet for this study

Summary

RATIONALE: Diagnostic procedures, such as technetium Tc 99m demobesin-4 followed by single-photon emission computer tomography, CT scan, and MRI, may help find prostate cancer and learn the extent of disease.

PURPOSE: This phase I trial is studying the side effects of technetium Tc 99m demobesin-4 and to see how well it works for imaging procedures in patients with prostate cancer.

Conditions

Interventions

OTHER

immunohistochemistry staining method

OTHER

laboratory biomarker analysis

OTHER

pharmacological study

PROCEDURE

computed tomography

PROCEDURE

magnetic resonance imaging

PROCEDURE

single photon emission computed tomography

RADIATION

technetium Tc 99m demobesin-4

Sponsors & Collaborators

Principal Investigators

  • Norbert Avril, MD · St. Bartholomew's Hospital

Study Design

Purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-06-30
Primary Completion
2011-12-31
Completion
2011-12-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00989105 on ClinicalTrials.gov